Home›Companies›Biotech & Pharma›Sinopia Biosciences

Sinopia Biosciences, Inc.

Develops medicines for people with Parkinson’s disease and other conditions.

Updated Nov 10, 2026·Latest SEC filing Jul 16, 2026·Suggest an edit

About Sinopia Biosciences

Sinopia Biosciences is a private company based in San Diego, California. It has reported $2,818,079 raised in one offering on Form D since July 2026. Its chief executive is Aarash Bordbar.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Jun 29, 2026Jul 16, 2026$2,818,079of $4.2M target35$80,517Equity, Securities on exerciseRule 506(b)Form D ↗

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Sinopia Biosciences's Form D filed Jul 16, 2026.

IF
Iman Famili
COO and director
AB
Aarash Bordbar
CEO, CSO, and Co-Founder, director
AS
BP
Bernhard Palsson
Co-Founder and director

Sources

  1. SECSinopia Biosciences, Inc. filing history
  2. CompanyMission
  3. CompanyNIH grant announcement